A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

A Study of ApricityRx™ Digital Therapeutic for Management of Immune-Related Adverse Events in Patients on Immuno-Oncology Therapy

Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.

Inclusion Criteria:

• Confirmed cancer diagnosis
• Prescribed treatment with immune-checkpoint inhibitor
• Age ≥ 18 years
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Uncomfortable with or unwilling to use digital or mobile technology
• Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow
• Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.